The $35 billion race to cure a silent killer that affects 30 million Americans

At the Mayo Clinic in Jacksonville, Florida, the liver transplant group is busy handling an onslaught of patients who have come from all over the country in hopes of a chance at life. For many, a liver transplant is their last hope, after being diagnosed with a deadly disease sweeping …

5 Biotech Stocks to Play the Sector’s Next Big Trend: NASH

The stars are aligning for several biotech stocks. Thirty-five billion stars in fact. That huge number in dollars represents the potential annual spending needed to treat one of the biggest and growing problems facing the healthcare sector today. We’re talking about NASH. Most often occurring in obese or glucose-intolerant people, …

Viking Therapeutics Announces Proposed Public Offering of Common Stock

Viking Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Viking also expects to grant to …

Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers

What’s the next massive multibillion-dollar market for the biopharmaceutical industry? Put an increasingly prevalent liver disease high on the list. Some analysts predict that the market for treatments of nonalcoholic steatohepatitis (NASH) could be between $20 billion and $35 billion. The progressive fatty liver disease is expected to become the …

Are These Red-Hot NASH Stocks Still a Buy?

Over the last two weeks, shares of Madrigal Pharmaceuticals (NASDAQ: MDGL), Galmed Pharmaceuticals (NASDAQ: GLMD), and Viking Therapeutics (NASDAQ: VKTX) have more than doubled in value. The reason? Each of these companies is developing a drug for a deadly form of fatty liver disease known as non-alcoholic steatohepatitis (NASH). The …